GlassScriptPhysician profile
Huong T Phan
NPI 1326059627
$2,750.64
in general payments reported to CMS, 2019-2025
34 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $431 · 2023: $685 · 2024: $998 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $482.59 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $377.35 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $354.72 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $264.61 | 2022-2025 | |
| Amgen INC. | $171.81 | 2022-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.18 | 2022-2025 | Jardiance |
| Abbott Laboratories | $113.28 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $106.21 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.62 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $88.07 | 2022-2025 | |
| Exact Sciences Corporation | $78.19 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $50.07 | 2022-2025 | Veozah |
| Gilead Sciences, INC. | $44.30 | 2022 | |
| Zimmer Biomet Holdings, INC. | $37.60 | 2025 | Rosa |
| Dynavax Technologies Corporation | $32.70 | 2024 | Heplisav-B |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $29.34 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.33 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.68 | 2022-2023 | Camzyos |
| Horizon Therapeutics Plc | $24.94 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $22.03 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $19.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.58 | 2023 | Trintellix |
| Glaxosmithkline, LLC. | $16.03 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Antares Pharma, INC. | $15.92 | 2023 | Xyosted, Tlando, Nocdurna |
| Lexicon Pharmaceuticals, INC. | $15.00 | 2024 | |
| Corcept Therapeutics | $14.94 | 2024 | Korlym |
| Medtronic, INC. | $14.63 | 2025 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.34 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $13.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.75 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $13.43 | 2024 | Voquezna |
| Inari Medical, INC. | $13.13 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Halozyme INC | $12.94 | 2023 | |
| Edwards Lifesciences Corporation | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huong Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.